Filing Error Slices Nearly Two Years Off Roche’s UK Lucentis Protection
Firms Warned To Take Care When Paying SPC Fees
Executive Summary
A ruling by the High Court should act as a warning to companies applying for supplementary protection certificates in the UK that they must make sure that the fees are paid for the full duration of the SPC, otherwise they could get a nasty surprise when it expires earlier than expected.
You may also be interested in...
Samsung Bioepis Adds To Biogen Collaboration
Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
Australia To Give Consumers More Formal Role In HTA Processes
The health department says consumers and patients should be able to initiate health technology assessments because many potentially helpful and lifesaving medicines might never be assessed for funding due to “a lack of commercial incentive for pharmaceutical companies.”
EC Defends Data Protection Cut As EU ‘Pharma Package’ Nears Crucial Milestone
Proposals to overhaul the general pharmaceutical legislation will ensure that the EU “continues to have one of the most generous systems of incentives in the world,” the European Commission says.